Are women with polycystic ovary syndrome resistant to activated protein C?

Fertil Steril. 2000 Dec;74(6):1229-32. doi: 10.1016/s0015-0282(00)01614-9.

Abstract

Objective: This study was performed to test the hypothesis that an increased prevalence of activated protein C (APC) resistance in women with polycystic ovary syndrome (PCOS) puts them at increased risk of miscarriage and thrombosis.

Design: Case control study.

Setting: A district general hospital in the United Kingdom.

Patient(s): Forty-one women with PCOS and 25 controls.

Intervention(s): Clinical histories, ultrasound scans, and venepunctures.

Main outcome measure(s): Diagnosis of PCOS or control, clinical histories, APC resistance according to an activated partial thromboplastin time-based assay.

Result(s): There was no significant difference in the proportion of women with APC resistance in both groups (three women in the PCOS group [7%] vs. one woman in the control group [4%]). The prevalence of APC resistance in the entire study population was 6.5%. In the PCOS group, 29% (12/41) gave a positive family history of thrombosis compared with 8% (2/25) in the control group. None of the women with a positive family history of thrombosis had abnormal antithrombin 111, protein C, or protein S levels.

Conclusion(s): This study suggests that women with PCOS may have the same prevalence of APC resistance as the background population and that APC resistance may not put them at a higher risk of thrombosis or miscarriage compared with the case of the general population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Spontaneous / etiology
  • Case-Control Studies
  • Drug Resistance
  • Female
  • Humans
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / physiopathology*
  • Protein C / physiology*
  • Reference Values
  • Risk Factors
  • Thrombosis / etiology
  • Thrombosis / genetics

Substances

  • Protein C